Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nucleic Acids Res ; 49(13): 7665-7679, 2021 07 21.
Artigo em Inglês | MEDLINE | ID: mdl-34157102

RESUMO

Deciphering translation is of paramount importance for the understanding of many diseases, and antibiotics played a pivotal role in this endeavour. Blasticidin S (BlaS) targets translation by binding to the peptidyl transferase center of the large ribosomal subunit. Using biochemical, structural and cellular approaches, we show here that BlaS inhibits both translation elongation and termination in Mammalia. Bound to mammalian terminating ribosomes, BlaS distorts the 3'CCA tail of the P-site tRNA to a larger extent than previously reported for bacterial ribosomes, thus delaying both, peptide bond formation and peptidyl-tRNA hydrolysis. While BlaS does not inhibit stop codon recognition by the eukaryotic release factor 1 (eRF1), it interferes with eRF1's accommodation into the peptidyl transferase center and subsequent peptide release. In human cells, BlaS inhibits nonsense-mediated mRNA decay and, at subinhibitory concentrations, modulates translation dynamics at premature termination codons leading to enhanced protein production.


Assuntos
Elongação Traducional da Cadeia Peptídica/efeitos dos fármacos , Terminação Traducional da Cadeia Peptídica/efeitos dos fármacos , Inibidores da Síntese de Proteínas/farmacologia , Microscopia Crioeletrônica , Células HeLa , Humanos , Degradação do RNAm Mediada por Códon sem Sentido/efeitos dos fármacos , Nucleosídeos/química , Nucleosídeos/farmacologia , Fatores de Terminação de Peptídeos/metabolismo , Peptídeos/metabolismo , Inibidores da Síntese de Proteínas/química , RNA Mensageiro/metabolismo , RNA de Transferência/química , RNA de Transferência/metabolismo , Subunidades Ribossômicas Maiores de Eucariotos/química , Subunidades Ribossômicas Maiores de Eucariotos/efeitos dos fármacos , Subunidades Ribossômicas Maiores de Eucariotos/metabolismo , Ribossomos/metabolismo
2.
Int J Cancer ; 147(4): 1059-1070, 2020 08 15.
Artigo em Inglês | MEDLINE | ID: mdl-31782150

RESUMO

Progress in the systemic control of osteosarcoma has been limited over the past decades thus indicating the urgent clinical need for the development of novel treatment strategies. Therefore, we have recently developed new preclinical models to study promising novel agents for the treatment of pediatric osteosarcoma. The checkpoint kinase (chk) inhibitor prexasertib (LY2606368) and its salt form (LSN2940930) have recently been shown to be active in adult and pediatric malignancies, including sarcoma. We have now tested the potency of prexasertib in clonogenic survival assays in two new lines of primary patient-derived osteosarcoma cells and in two established osteosarcoma cell lines as a single agent and in combination with cisplatin and the poly ADP-ribose polymerase (PARP) inhibitor talazoparib. Prexasertib alone results in strongly reduced clonogenic survival at low nanomolar concentrations and acts by affecting cell cycle progression, induction of apoptosis and induction of double-stranded DNA breakage at concentrations that are well below clinically tolerable and safe plasma concentrations. In combination with cisplatin and talazoparib, prexasertib acts in a synergistic fashion. Chk1 inhibition by prexasertib and its combination with the DNA damaging agent cisplatin and the PARP-inhibitor talazoparib thus emerges as a potential new treatment option for pediatric osteosarcoma which will now have to be tested in preclinical primary patient derived in vivo models and clinical studies.


Assuntos
Apoptose/efeitos dos fármacos , Cisplatino/farmacologia , Osteossarcoma/tratamento farmacológico , Ftalazinas/farmacologia , Pirazinas/farmacologia , Pirazóis/farmacologia , Ensaios Antitumorais Modelo de Xenoenxerto/métodos , Animais , Antineoplásicos/farmacologia , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Células Clonais/efeitos dos fármacos , Sinergismo Farmacológico , Humanos , Camundongos , Osteossarcoma/patologia , Inibidores de Proteínas Quinases/farmacologia
3.
EMBO J ; 36(20): 2968-2986, 2017 10 16.
Artigo em Inglês | MEDLINE | ID: mdl-28899899

RESUMO

Nonsense-mediated mRNA decay (NMD) is a cellular surveillance pathway that recognizes and degrades mRNAs with premature termination codons (PTCs). The mechanisms underlying translation termination are key to the understanding of RNA surveillance mechanisms such as NMD and crucial for the development of therapeutic strategies for NMD-related diseases. Here, we have used a fully reconstituted in vitro translation system to probe the NMD proteins for interaction with the termination apparatus. We discovered that UPF3B (i) interacts with the release factors, (ii) delays translation termination and (iii) dissociates post-termination ribosomal complexes that are devoid of the nascent peptide. Furthermore, we identified UPF1 and ribosomes as new interaction partners of UPF3B. These previously unknown functions of UPF3B during the early and late phases of translation termination suggest that UPF3B is involved in the crosstalk between the NMD machinery and the PTC-bound ribosome, a central mechanistic step of RNA surveillance.


Assuntos
Terminação Traducional da Cadeia Peptídica , Proteínas de Ligação a RNA/metabolismo , Linhagem Celular , Humanos , Degradação do RNAm Mediada por Códon sem Sentido
4.
RNA ; 17(5): 843-54, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21389146

RESUMO

The degradation of nonsense-mutated ß-globin mRNA by nonsense-mediated mRNA decay (NMD) limits the synthesis of C-terminally truncated dominant negative ß-globin chains and thus protects the majority of heterozygotes from symptomatic ß-thalassemia. ß-globin mRNAs with nonsense mutations in the first exon are known to bypass NMD, although current mechanistic models predict that such mutations should activate NMD. A systematic analysis of this enigma reveals that (1) ß-globin exon 1 is bisected by a sharp border that separates NMD-activating from NMD-bypassing nonsense mutations and (2) the ability to bypass NMD depends on the ability to reinitiate translation at a downstream start codon. The data presented here thus reconcile the current mechanistic understanding of NMD with the observed failure of a class of nonsense mutations to activate this important mRNA quality-control pathway. Furthermore, our data uncover a reason why the position of a nonsense mutation alone does not suffice to predict the fate of the affected mRNA and its effect on protein expression.


Assuntos
Códon sem Sentido , Éxons , Estabilidade de RNA , Transcrição Gênica , Globinas beta/genética , Células HeLa , Humanos , Globinas beta/metabolismo
5.
J Clin Microbiol ; 43(11): 5622-7, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16272495

RESUMO

IS6110 restriction fragment length polymorphism (RFLP) analysis is the most widely applied method for strain differentiation of Mycobacterium tuberculosis complex. We have previously described mixed-linker PCR, an IS6110-based PCR method that favorably compared with other typing methods for M. tuberculosis complex according to reproducibility and ability to differentiate between strains. Here we report the further development of this method, called fast ligation-mediated PCR (FLiP), which allows analysis of strains within one working day and starting from less than 1 ng of mycobacterial DNA or a crude cell lysate. Blinded analysis of a standard set of 131 M. tuberculosis complex and nontuberculous isolates showed the ability to differentiate 81 types among 90 M. tuberculosis complex isolates with 84 different IS6110 RFLP fingerprint patterns and detected 97% of the 31 duplicate samples. We suggest that FLiP can serve to rapidly detect chains of transmission prior to starting high-throughput analysis or standard IS6110 RFLP. It may as well serve as a secondary typing technique for other, non-IS6110-based methods.


Assuntos
Técnicas de Tipagem Bacteriana , Elementos de DNA Transponíveis/genética , Mycobacterium tuberculosis/classificação , Reação em Cadeia da Polimerase/métodos , DNA Bacteriano/genética , Amplificação de Genes , Mycobacterium tuberculosis/genética , Oligonucleotídeos/biossíntese , Reprodutibilidade dos Testes , Sensibilidade e Especificidade
6.
J Clin Microbiol ; 40(5): 1869-72, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-11980981

RESUMO

A PCR assay based on the simultaneous detection of IS1245 and IS1311 was developed and used to determine the host range of these insertion elements. Specific PCR products were observed in Mycobacterium malmoense, Mycobacterium scrofulaceum, and Mycobacterium nonchromogenicum, indicating that IS1245 and IS1311 are not limited to the Mycobacterium avium complex.


Assuntos
Elementos de DNA Transponíveis , Mycobacterium/genética , Micobactérias não Tuberculosas/genética , Primers do DNA , DNA Bacteriano/genética , Genes Bacterianos , Mycobacterium/classificação , Mycobacterium avium/classificação , Mycobacterium avium/genética , Mycobacterium scrofulaceum/classificação , Mycobacterium scrofulaceum/genética , Micobactérias não Tuberculosas/classificação , Hibridização de Ácido Nucleico , Reação em Cadeia da Polimerase/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...